August 2010
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p1
Trade Publication
The article reports on the claim of Compugen Ltd. that using CGEN-15001 in an animal model of multiple sclerosis (MS) can completely remove spontaneous relapses. The firm added that the administration of this novel molecule prior to disease onset is able to make a pronounced delay of disease onset and a significant decrease in disease symptoms. Professor Stephen Miller from Northwestern University commented that the findings are unique among the molecules targeting the B7 family of co-stimulatory molecules that have been published to date.


Related Articles

  • Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article presents information on an announcement made by Compugen Ltd. on the results of the initial validation of CGEN-15031 and CGEN-15051, the additional therapeutic product candidates in animal models of autoimmune diseases. The study of CGEN-15031 in the experimental autoimmune...

  • Unlocking the Puzzle of Progression. O'Dell, Holly // Momentum (19403410);Summer2011, Vol. 4 Issue 3, p24 

    The article discusses the diagnosis and treatment of progressive multiple sclerosis (PMS). It states that magnetic resonance imaging (MRI) is one of the most important tools detecting the disease, but it is impossible to determine what type a person has from an MRI scan alone since imaging is...

  • The patient's journey: multiple sclerosis.  // BMJ: British Medical Journal (International Edition);4/16/2005, Vol. 330 Issue 7496, p885 

    Offers a view of what a person newly diagnosed with multiple sclerosis. Good news versus bad news; The beginning symptoms of multiple sclerosis; Role of the patient's spouse.

  • What Is Progressive MS? Wolinsky, Jerry // Inside MS;Jan2005, Vol. 23 Issue 1, p56 

    Discusses the symptoms and clinical features of progressive multiple sclerosis (MS). Difference between primary-progressive MS and secondary-progressive MS; Accumulation of disability in people with relapsing-remitting MS in a slow manner; Diagnostic criteria used to determine if a person has a...

  • Multiple Sclerosis in Iran: A Demographic Study of 8,000 Patients and Changes over Time. Sahraian, Mohammad Ali; Khorramnia, Saeideh; Ebrahim, Mina Mohammad; Moinfar, Zahra; Lotfi, Jamshid; Pakdaman, Hossien // European Neurology;2010, Vol. 64 Issue 6, p331 

    Background: Iran was formerly considered to be located in a low prevalence zone for multiple sclerosis (MS). During the last decade the number of patients has increased. This study was conducted to estimate the prevalence of MS in the capital city of the country. Methods: We re-evaluated the...

  • MS symptoms.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p34 

    Discusses abstracts of studies about symptoms of multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "Clinical Profile of Multiple Sclerosis Patients in Wisconsin, USA," by B. Khatri and colleagues; "The First Clinical Findings in Iranian MS Patients,"...

  • Lesley's story: a case report, and discussion of challenges faced in end-of-life care for progressive neurological disease. Foley, Peter; Hampton, Justine; Hampton, Andy; Hampton, Ruth; Oleksy, Danny; Oliver, David; J. Weller, Belinda // Practical Neurology (BMJ Publishing Group);Aug2012, Vol. 12 Issue 4, p244 

    The article presents a case study of Lesley Ruth Hampton, a 42-year-old woman who died from complications of multiple sclerosis (MS) in hospital. Some of the challenges faced by Lesley in end-of-life care for progressive neurological disease are described. The article discusses the need for...

  • Evolving Treatment Strategies in the Management of Multiple Sclerosis. Derwenskus, Joy // Journal of Managed Care Medicine;2013, Vol. 16 Issue 3, p16 

    No abstract available.

  • Assessing changes in relapse rates in multiple sclerosis. Inusah, Seidu; Sormani, Maria P.; Cofield, Stacey S.; Aban, Inmaculada B.; Musani, Solomon K.; Srinivasasainagendra, Vinodh; Cutter, Gary R. // Multiple Sclerosis (13524585);12/01/2010, Vol. 16 Issue 12, p1414 

    Multiple Sclerosis (MS) annualized relapse rates (ARRs) in trials may be declining due to changes in diagnostic criteria, MS etiology, study criteria, and selection biases. This review examines if there is a trend in the ARR for relapsing—remitting MS patients (RRMS) over time and if so,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics